secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2026-08-20T20:06:14+00:00
Accession:  0001193125-26-359185
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf sells pre-clinical INDUCER and INDUKINE platforms to EMD Serono for $28M upfront plus $5M
--------------------------------------------------------------------------------

- Closed Aug 14, 2026 asset sale to EMD Serono: $28M upfront plus $5M upon transfer completion.
- Sale covers pre-clinical INDUCER and INDUKINE platforms; excludes WTX-124 and WTX-330 clinical programs.
- Company retains rights to advance WTX-124 and WTX-330; EMD grants exclusive license to related patents.
- License agreement enables sublicenses to Harpoon and Jazz under existing agreements; 24-month non-compete.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000119312526359185/0001193125-26-359185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000119312526359185/d141219d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-359185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer